Espinoza, Janyra A.León, Miguel A.Céspedes, Pablo F.Gómez, Roberto S.Canedo-Marroquín, GiselaRiquelme, Sebastían A.Salazar-Echegarai, Francisco J.Blancou, PhillipeSimon, ThomasAnegon, IgnacioLay, Margarita K.González, Pablo A.Riedel, Claudia A.Bueno, Susan M.Kalergis, Alexis M.2024-04-302024-04-302017-07Journal of Immunology Volume 199, Issue 1, Pages 212 - 2231 July 20170022-1767https://repositorio.unab.cl/handle/ria/56488Indexación: ScopusHuman respiratory syncytial virus (hRSV) is the leading cause of severe lower respiratory tract infections in children. The development of novel prophylactic and therapeutic antiviral drugs against hRSV is imperative to control the burden of disease in the susceptible population. In this study, we examined the effects of inducing the activity of the host enzyme heme oxygenase-1 (HO-1) on hRSV replication and pathogenesis on lung inflammation induced by this virus. Our results show that after hRSV infection, HO-1 induction with metalloporphyrin cobalt protoporphyrin IX significantly reduces the loss of body weight due to hRSV-induced disease. Further, HO-1 induction also decreased viral replication and lung inflammation, as evidenced by a reduced neutrophil infiltration into the airways, with diminished cytokine and chemokine production and reduced T cell function. Concomitantly, upon cobalt protoporphyrin IX treatment, there is a significant upregulation in the production of IFN-α/β mRNAs in the lungs. Furthermore, similar antiviral and protective effects occur by inducing the expression of human HO-1 in MHC class II+ cells in transgenic mice. Finally, in vitro data suggest that HO-1 induction can modulate the susceptibility of cells, especially the airway epithelial cells, to hRSV infection. Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved.enArtículoCC BY 4.0 DEED Atribución 4.0 Internacional10.4049/jimmunol.1601414